Lizet Sanchez
Research Subjects
Lizet Sanchez has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Agustin Lage
Center of Molecular Immunology
6 shared publicationsPatricia Lorenzo-Luaces
Center of Molecular Immunology
5 shared publications- Patricia Lorenzo-Luaces
CIM: Centro de Inmunologia Molecular
5 shared publications - Tania Crombet
Center of Molecular Immunology, Havana, Cuba
4 shared publications - Agustin Lage
Clinical Research Division, Center of Molecular Immunology, Calle 216 esq 15. Atabey, 11600, Havana, Cuba
3 shared publications Ariel Alonso
I-Biostat Catholic University of Leuven
3 shared publications
Latest Publications
- 1 February 2026
- Published by Springer Nature
- p. 685-696
Platform for the Integration and Analysis of Clinical Data at the Center of Molecular Immunology
- 1 February 2026
- Published by Springer Nature
- p. 685-696
Platform for the Integration and Analysis of Clinical Data at the Center of Molecular Immunology
- 22 October 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (3) , 1422-1435
NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study
Background: NeuroEPO plus is a recombinant erythropoietin with a sialic acid content like that produced by astrocytes, lacking the hematopoietic activity of conventional erythropoietin. Objective: To evaluate the efficacy and safety of treatment with neuroEPO plus. Methods: It was a post-trial observational follow-up study with four groups, NE: subjects who continued treatment with neuroEPO plus after trial, PB-NE: subjects who received a placebo during the trial and then receive neuroEPO plus, NE-CTRL: subjects who received neuroEPO plus during the trial and then interrupted treatment and CTRL: subjects who were never treated. NeuroEPO plus was administrated three times a week nasally. The primary outcome was changed from baseline in the score on the11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog11) at 96 weeks. Secondary outcomes included Global Deterioration Scale, Montreal Cognitive Assessment, Neuropsychiatric Inventory, and Lawton Instrumental Activities of Daily Living Scale. Results: The adjusted median change from baseline in the ADAS-Cog11 score at 96 weeks was −6.0 in NE group and 11.0 in the CTRL group (difference, 21.0; 95% confidence interval [CI], 14.6–27.4; p = 0.000), −1.0 in the PB-NE (difference, 15.4; 95% CI, 9.0–21.8; p = 0.000) and 4.0 in the NE-CTRL (difference, 8.3; 95% CI, 1.4–15.2; p = 0.011). The results for secondary outcomes showed statistically significant differences. Conclusions: Subjects who continued or started treatment with neuroEPO plus stabilized or slowed down the progression of the disease. These results and the method of drug administration, make neuroEPO plus an attractive option to consider for Alzheimer's disease patients.
- 22 October 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (3) , 1422-1435
NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study
Background: NeuroEPO plus is a recombinant erythropoietin with a sialic acid content like that produced by astrocytes, lacking the hematopoietic activity of conventional erythropoietin. Objective: To evaluate the efficacy and safety of treatment with neuroEPO plus. Methods: It was a post-trial observational follow-up study with four groups, NE: subjects who continued treatment with neuroEPO plus after trial, PB-NE: subjects who received a placebo during the trial and then receive neuroEPO plus, NE-CTRL: subjects who received neuroEPO plus during the trial and then interrupted treatment and CTRL: subjects who were never treated. NeuroEPO plus was administrated three times a week nasally. The primary outcome was changed from baseline in the score on the11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog11) at 96 weeks. Secondary outcomes included Global Deterioration Scale, Montreal Cognitive Assessment, Neuropsychiatric Inventory, and Lawton Instrumental Activities of Daily Living Scale. Results: The adjusted median change from baseline in the ADAS-Cog11 score at 96 weeks was −6.0 in NE group and 11.0 in the CTRL group (difference, 21.0; 95% confidence interval [CI], 14.6–27.4; p = 0.000), −1.0 in the PB-NE (difference, 15.4; 95% CI, 9.0–21.8; p = 0.000) and 4.0 in the NE-CTRL (difference, 8.3; 95% CI, 1.4–15.2; p = 0.011). The results for secondary outcomes showed statistically significant differences. Conclusions: Subjects who continued or started treatment with neuroEPO plus stabilized or slowed down the progression of the disease. These results and the method of drug administration, make neuroEPO plus an attractive option to consider for Alzheimer's disease patients.
- Open Access
- 30 June 2023
- Published by Poznań University of Economics and Business in La Revue Internationale des Économistes de Langue Française
- Vol. 8 (1) , 34-48
Prévision à court terme en temps réel de l'épidémie de COVID-19 à Cuba en utilisant la modélisation
En l'absence d'information fiable sur les mécanismes de transmission d'une infection émergente, de simples modèles phénoménologiques peuvent apporter une estimation précoce de l'étendue potentielle d'épidémies en temps réel. Un avertissement sur la taille finale d'une épidémie et en particulier de la COVID-19 actuellement actif peut servir aux autorités sanitaires pour y faire face. Une variété de modèles non-linéaires ont été développés pour définir les cas cumulés de maladies épidémiques infectieuses (e.g. Richards, logistique, modèles Gompertz). Tous ces modèles peuvent utiliser correctement les données pour obtenir des prévisions à court terme en temps réel. Typiquement, il s'agit de suivre la procédure d'estimation post-sélection, i.e., de sélectionner un modèle parmi tous ceux disponibles et d'ignorer ceux reposant sur l'incertitude dans l'estimation et l'inférence vu que ces procédures sont basées sur un seul modèle. Dans ce travail, nous établissons une prédiction en temps réel de la taille finale, point crucial de l'épidémie, et des prévisions 10 jours à l'avance de cas cumulatifs en utilisant plusieurs modèles non-linéaires où ces paramètres sont estimés via modélisation. La méthode est appliquée à l'épidémie de COVID-19 en 2020 à Cuba.
- 30 June 2023
- Published by Poznań University of Economics and Business in La Revue Internationale des Économistes de Langue Française
- Vol. 8 (1) , 34-48
Open AccessPrévision à court terme en temps réel de l'épidémie de COVID-19 à Cuba en utilisant la modélisation
En l'absence d'information fiable sur les mécanismes de transmission d'une infection émergente, de simples modèles phénoménologiques peuvent apporter une estimation précoce de l'étendue potentielle d'épidémies en temps réel. Un avertissement sur la taille finale d'une épidémie et en particulier de la COVID-19 actuellement actif peut servir aux autorités sanitaires pour y faire face. Une variété de modèles non-linéaires ont été développés pour définir les cas cumulés de maladies épidémiques infectieuses (e.g. Richards, logistique, modèles Gompertz). Tous ces modèles peuvent utiliser correctement les données pour obtenir des prévisions à court terme en temps réel. Typiquement, il s'agit de suivre la procédure d'estimation post-sélection, i.e., de sélectionner un modèle parmi tous ceux disponibles et d'ignorer ceux reposant sur l'incertitude dans l'estimation et l'inférence vu que ces procédures sont basées sur un seul modèle. Dans ce travail, nous établissons une prédiction en temps réel de la taille finale, point crucial de l'épidémie, et des prévisions 10 jours à l'avance de cas cumulatifs en utilisant plusieurs modèles non-linéaires où ces paramètres sont estimés via modélisation. La méthode est appliquée à l'épidémie de COVID-19 en 2020 à Cuba.
- Open Access
- 1 January 2023
- Published by Wiley in BioMed Research International
- Vol. 2023 (1)
Nimotuzumab Concurrent with Gemcitabine as First‐Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Background. Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells. Methods. A prospective, nonrandomized, uncontrolled, open‐label, and multicenter clinical trial was conducted to evaluate the safety and effectiveness of nimotuzumab combined with gemcitabine as first‐line treatment in unresectable locally advanced or metastatic pancreatic tumors in a real‐world condition. Adverse events, their intensity, severity, and causality were determined using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.0). Median overall survival, median progression‐free survival, and 1‐ and 2‐year survival rates were determined by using the Kaplan‐Meier. Results. 69 patients were included. The proportion of related serious adverse events was 1.2%. The most frequent adverse events were nausea (10%), anemia (8%), and abdominal pain (8%). Objective response was achieved in 18.5% of the patients and disease control in 43.1%. Patients with locally advanced disease achieved a median overall survival of 16.36 months (95% CI; 14.35‐18.38); 1‐ and 2‐year survival rates of 72.2 and 29.2 months, respectively; a median progression‐free survival of 9.6 months (95% CI; 4.91‐14.20); and a 1‐year progression‐free survival rate of 39%. Patients with metastatic disease achieved a median survival of 6.23 months (95% CI; 4.32‐8.13); 1‐ and 2‐year survival rates of 18.1 and 3.0 months, respectively; a median progression‐free survival of 7.6 months (95% CI; 6.08‐9.90); and 1‐ and 2‐year PFS rates of 20.5 and 5.1 months, respectively. Conclusions. Nimotuzumab combined with gemcitabine represents a safe and effective first‐line treatment option for patients with advanced pancreatic adenocarcinoma in real‐world conditions. Survival benefits were increased in those patients who received 8 or more doses of nimotuzumab. This trial is registered with RPCEC00000245 in the Cuban Registry of Clinical Trials, part of the World Health Organization’s International Clinical Trials Registry Platform (ICTRP).
- 1 January 2023
- Published by Wiley in BioMed Research International
- Vol. 2023 (1)
Open AccessNimotuzumab Concurrent with Gemcitabine as First‐Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Background. Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells. Methods. A prospective, nonrandomized, uncontrolled, open‐label, and multicenter clinical trial was conducted to evaluate the safety and effectiveness of nimotuzumab combined with gemcitabine as first‐line treatment in unresectable locally advanced or metastatic pancreatic tumors in a real‐world condition. Adverse events, their intensity, severity, and causality were determined using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.0). Median overall survival, median progression‐free survival, and 1‐ and 2‐year survival rates were determined by using the Kaplan‐Meier. Results. 69 patients were included. The proportion of related serious adverse events was 1.2%. The most frequent adverse events were nausea (10%), anemia (8%), and abdominal pain (8%). Objective response was achieved in 18.5% of the patients and disease control in 43.1%. Patients with locally advanced disease achieved a median overall survival of 16.36 months (95% CI; 14.35‐18.38); 1‐ and 2‐year survival rates of 72.2 and 29.2 months, respectively; a median progression‐free survival of 9.6 months (95% CI; 4.91‐14.20); and a 1‐year progression‐free survival rate of 39%. Patients with metastatic disease achieved a median survival of 6.23 months (95% CI; 4.32‐8.13); 1‐ and 2‐year survival rates of 18.1 and 3.0 months, respectively; a median progression‐free survival of 7.6 months (95% CI; 6.08‐9.90); and 1‐ and 2‐year PFS rates of 20.5 and 5.1 months, respectively. Conclusions. Nimotuzumab combined with gemcitabine represents a safe and effective first‐line treatment option for patients with advanced pancreatic adenocarcinoma in real‐world conditions. Survival benefits were increased in those patients who received 8 or more doses of nimotuzumab. This trial is registered with RPCEC00000245 in the Cuban Registry of Clinical Trials, part of the World Health Organization’s International Clinical Trials Registry Platform (ICTRP).
- 29 December 2022
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 18, 100422
Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366
- 29 December 2022
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 18, 100422
Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366
- Open Access
- 24 September 2022
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 16, 100366
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study
- 24 September 2022
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 16, 100366
Open AccessCuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study
- Open Access
- 17 August 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-8
Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non–Small Cell Lung Cancer Patients. Methods: Data from a controlled clinical trial evaluating the effect of CIMAvax-EGF were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive causal information (PCI) was calculated for all possible models. The model with a minimum number of predictors, but with high prediction accuracy (PCI > 0.7) was selected. Good, rare and poor responder patients were identified using the predictive probability of treatment success. Results: The mean of PCI increased from 0.486, when only one predictor is considered, to 0.98 using the multivariate approach with all predictors. The model considering the proportion of CD4+ T cell, basal Epidermal Growth Factor (EGF) concentration, neutrophil to lymphocyte ratio, Monocytes, and Neutrophils as predictors were selected (PCI > 0.74). Patients predicted as good responders according to the pre-treatment biomarkers values treated with CIMAvax-EGF had a significant higher observed survival compared with the control group (p = 0.03). No difference was observed for bad responders. Conclusions: Peripheral blood parameters and immunosenescence biomarkers together with basal EGF concentration in serum resulted in good predictors of the CIMAvax-EGF success in advanced NSCLC. Future research should explore molecular and genetic profile as biomarkers for CIMAvax-EGF and it combination with immune-checkpoint inhibitors. The study illustrates the application of a new methodology, based on causal inference, to evaluate multivariate pre-treatment predictors. The multivariate approach allows realistic predictions of the clinical benefit of patients and should be introduced in daily clinical practice.
- 17 August 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-8
Open AccessIdentifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non–Small Cell Lung Cancer Patients. Methods: Data from a controlled clinical trial evaluating the effect of CIMAvax-EGF were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive causal information (PCI) was calculated for all possible models. The model with a minimum number of predictors, but with high prediction accuracy (PCI > 0.7) was selected. Good, rare and poor responder patients were identified using the predictive probability of treatment success. Results: The mean of PCI increased from 0.486, when only one predictor is considered, to 0.98 using the multivariate approach with all predictors. The model considering the proportion of CD4+ T cell, basal Epidermal Growth Factor (EGF) concentration, neutrophil to lymphocyte ratio, Monocytes, and Neutrophils as predictors were selected (PCI > 0.74). Patients predicted as good responders according to the pre-treatment biomarkers values treated with CIMAvax-EGF had a significant higher observed survival compared with the control group (p = 0.03). No difference was observed for bad responders. Conclusions: Peripheral blood parameters and immunosenescence biomarkers together with basal EGF concentration in serum resulted in good predictors of the CIMAvax-EGF success in advanced NSCLC. Future research should explore molecular and genetic profile as biomarkers for CIMAvax-EGF and it combination with immune-checkpoint inhibitors. The study illustrates the application of a new methodology, based on causal inference, to evaluate multivariate pre-treatment predictors. The multivariate approach allows realistic predictions of the clinical benefit of patients and should be introduced in daily clinical practice.
- Open Access
- 12 August 2020
- Published by Springer Nature in Research Square
Identifying predictive biomarkers of CIMAvaxEGF success in Non–Small Cell Lung Cancer Patients.
Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non–Small Cell Lung Cancer Patients. Methods: Data from a controlled clinical trial evaluating the effect of CIMAvax-EGF were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive causal information (PCI) was calculated for all possible models. The model with a minimum number of predictors, but with high prediction accuracy (PCI>0.7) was selected. Good, rare and poor responder patients were identified using the predictive probability of treatment success. Results: The mean of PCI increased from 0.486, when only one predictor is considered, to 0.98 using the multivariate approach with all predictors. The model considering the proportion of CD4+ T cell, basal Epidermal Growth Factor (EGF) concentration, neutrophil to lymphocyte ratio, Monocytes, and Neutrophils as predictors were selected (PCI>0.74). Patients predicted as good responders according to the pre-treatment biomarkers values treated with CIMAvax-EGF had a significant higher observed survival compared with the control group (p=0.03). No difference was observed for bad responders. Conclusions: Peripheral blood parameters and immunosenescence biomarkers together with basal EGF concentration in serum resulted in good predictors of the CIMAvax-EGF success in advanced NSCLC. Future research should explore molecular and genetic profile as biomarkers for CIMAvax-EGF and it combination with immune-checkpoint inhibitors. The study illustrates the application of a new methodology, based on causal inference, to evaluate multivariate pre-treatment predictors. The multivariate approach allows realistic predictions of the clinical benefit of patients and should be introduced in daily clinical practice.
- 12 August 2020
- Published by Springer Nature in Research Square
Open AccessIdentifying predictive biomarkers of CIMAvaxEGF success in Non–Small Cell Lung Cancer Patients.
Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non–Small Cell Lung Cancer Patients. Methods: Data from a controlled clinical trial evaluating the effect of CIMAvax-EGF were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive causal information (PCI) was calculated for all possible models. The model with a minimum number of predictors, but with high prediction accuracy (PCI>0.7) was selected. Good, rare and poor responder patients were identified using the predictive probability of treatment success. Results: The mean of PCI increased from 0.486, when only one predictor is considered, to 0.98 using the multivariate approach with all predictors. The model considering the proportion of CD4+ T cell, basal Epidermal Growth Factor (EGF) concentration, neutrophil to lymphocyte ratio, Monocytes, and Neutrophils as predictors were selected (PCI>0.74). Patients predicted as good responders according to the pre-treatment biomarkers values treated with CIMAvax-EGF had a significant higher observed survival compared with the control group (p=0.03). No difference was observed for bad responders. Conclusions: Peripheral blood parameters and immunosenescence biomarkers together with basal EGF concentration in serum resulted in good predictors of the CIMAvax-EGF success in advanced NSCLC. Future research should explore molecular and genetic profile as biomarkers for CIMAvax-EGF and it combination with immune-checkpoint inhibitors. The study illustrates the application of a new methodology, based on causal inference, to evaluate multivariate pre-treatment predictors. The multivariate approach allows realistic predictions of the clinical benefit of patients and should be introduced in daily clinical practice.
- Open Access
- 25 March 2020
- Published by Springer Nature in Research Square
Identifying predictive biomarkers of CIMAvaxEGF success in Non–Small Cell Lung Cancer Patients
Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non–Small Cell Lung Cancer Patients. Methods: Data from a clinical trial evaluating the effect on survival time of CIMAvax-EGF versus best supportive care were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive causal information (PCI) was calculated for all possible models. The model with a minimum number of predictors, but with high prediction accuracy (PCI>0.7) was selected. Good, rare and poor responder patients were identified using the predictive probability of treatment success. Results: The mean of PCI increased from 0.486, when only one predictor is considered, to 0.98 using the multivariate approach with all predictors. The model considering the proportion of CD4+ T cell, basal Epidermal Growth Factor (EGF) concentration, neutrophil to lymphocyte ratio, Monocytes, and Neutrophils as predictors were selected (PCI>0.74). Patients predicted as good responders according to the pre-treatment biomarkers values treated with CIMAvax-EGF had a significant higher observed survival compared with the control group (p=0.03). No difference was observed for bad responders. Conclusions: Peripheral blood parameters and immunosenescence biomarkers together with basal EGF concentration in serum resulted in good predictors of the CIMAvax-EGF success in advanced NSCLC. Future research should explore molecular and genetic profile as biomarkers for CIMAvax-EGF and it combination with immune-checkpoint inhibitors. The study illustrates the application of a new methodology, based on causal inference, to evaluate multivariate pre-treatment predictors. The multivariate approach allows realistic predictions of the clinical benefit of patients and should be introduced in daily clinical practice.
- 25 March 2020
- Published by Springer Nature in Research Square
Open AccessIdentifying predictive biomarkers of CIMAvaxEGF success in Non–Small Cell Lung Cancer Patients
Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately as possible predictive markers of immunotherapy. Here, we illustrate the use of a causal inference model to identify predictive biomarkers of CIMAvaxEGF success in the treatment of Non–Small Cell Lung Cancer Patients. Methods: Data from a clinical trial evaluating the effect on survival time of CIMAvax-EGF versus best supportive care were analyzed retrospectively, following a causal inference approach. Pre-treatment potential predictive biomarkers included basal serum EGF concentration, peripheral blood parameters and immunosenescence biomarkers. The proportion of CD8 + CD28- T cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. The 33 patients with complete information were included. The predictive causal information (PCI) was calculated for all possible models. The model with a minimum number of predictors, but with high prediction accuracy (PCI>0.7) was selected. Good, rare and poor responder patients were identified using the predictive probability of treatment success. Results: The mean of PCI increased from 0.486, when only one predictor is considered, to 0.98 using the multivariate approach with all predictors. The model considering the proportion of CD4+ T cell, basal Epidermal Growth Factor (EGF) concentration, neutrophil to lymphocyte ratio, Monocytes, and Neutrophils as predictors were selected (PCI>0.74). Patients predicted as good responders according to the pre-treatment biomarkers values treated with CIMAvax-EGF had a significant higher observed survival compared with the control group (p=0.03). No difference was observed for bad responders. Conclusions: Peripheral blood parameters and immunosenescence biomarkers together with basal EGF concentration in serum resulted in good predictors of the CIMAvax-EGF success in advanced NSCLC. Future research should explore molecular and genetic profile as biomarkers for CIMAvax-EGF and it combination with immune-checkpoint inhibitors. The study illustrates the application of a new methodology, based on causal inference, to evaluate multivariate pre-treatment predictors. The multivariate approach allows realistic predictions of the clinical benefit of patients and should be introduced in daily clinical practice.
- Open Access
- 6 December 2019
- Published by Springer Nature in Research Square
Mixture survival models methodology: an application to cancer immunotherapy assessment in clinical trials
Progress in immunotherapy revolutionized the treatment landscape for advanced lung cancer, raising survival expectations beyond those that were historically anticipated with this disease. In the present study, we describe the methods for the adjustment of mixture parametric models of two populations for survival analysis in the presence of long survivors. A methodology is proposed in several five steps: first, it is proposed to use the multimodality test to decide the number of subpopulations to be considered in the model, second to adjust simple parametric survival models and mixture distribution models, to estimate the parameters and to select the best model fitted the data, finally, to test the hypotheses to compare the effectiveness of immunotherapies in the context of randomized clinical trials. The methodology is illustrated with data from a clinical trial that evaluates the effectiveness of the therapeutic vaccine CIMAvaxEGF vs the best supportive care for the treatment of advanced lung cancer. The mixture survival model allows estimating the presence of a subpopulation of long survivors that is 44% for vaccinated patients. The differences between the treated and control group were significant in both subpopulations (population of short-term survival: p = 0.001, the population of long-term survival: p = 0.0002). For cancer therapies, where a proportion of patients achieves long-term control of the disease, the heterogeneity of the population must be taken into account. Mixture parametric models may be more suitable to detect the effectiveness of immunotherapies compared to standard models.
- 6 December 2019
- Published by Springer Nature in Research Square
Open AccessMixture survival models methodology: an application to cancer immunotherapy assessment in clinical trials
Progress in immunotherapy revolutionized the treatment landscape for advanced lung cancer, raising survival expectations beyond those that were historically anticipated with this disease. In the present study, we describe the methods for the adjustment of mixture parametric models of two populations for survival analysis in the presence of long survivors. A methodology is proposed in several five steps: first, it is proposed to use the multimodality test to decide the number of subpopulations to be considered in the model, second to adjust simple parametric survival models and mixture distribution models, to estimate the parameters and to select the best model fitted the data, finally, to test the hypotheses to compare the effectiveness of immunotherapies in the context of randomized clinical trials. The methodology is illustrated with data from a clinical trial that evaluates the effectiveness of the therapeutic vaccine CIMAvaxEGF vs the best supportive care for the treatment of advanced lung cancer. The mixture survival model allows estimating the presence of a subpopulation of long survivors that is 44% for vaccinated patients. The differences between the treated and control group were significant in both subpopulations (population of short-term survival: p = 0.001, the population of long-term survival: p = 0.0002). For cancer therapies, where a proportion of patients achieves long-term control of the disease, the heterogeneity of the population must be taken into account. Mixture parametric models may be more suitable to detect the effectiveness of immunotherapies compared to standard models.